Evaluation on the effect of acesodyne treatment in patient with lung cancer bone metastasis
Abstract：BACKGROUND: Whether the application of osteoclast activity depressant represented by Pamidronate can relieve the pain induced by lung cancer bone metastasis becomes a problem worth investigation in the treatment of the patients with lung cancer bone metastasis.OBJECTIVE: To evaluate the effectiveness of acesodyne by Pamidronate group of medicines in,the treatment against cancer in patients with lung cancer bone metastasis as well as the quality of life after therapy.DESIGN: A randomized controlled trial SETTING and PARTICIPANTS: Seventy-one cases of lung cancer bone metastasis patients admitted by the Second Affiliated Hospital of Jinan University, Shenzhen City People' s Hospital from January 1996 to June 1998were grouped into integrate therapy group( n =46) and mono-therapy group (n =25) . Integrate therapy group was divided into three subgroups:chemotherapy + Pamidronate Disodium (PD) subgroup( n = 18), radiotherapy + PD subgroup( n = 16), and nuclide + PD subgroup( n = 12). Mono-the-rapy group was divided into two subgroups: chemotherapy subgroup( n = 15 )and radiotherapy subgroup( n = 10).INTERVENTIONS: Integrate therapy of PD combined with chemotherapy,radiotherapy and nuclide and mono-therapy of chemotherapy and radiotherapy were introduced respectively in the above corresponding groups. The therapeutic effectiveness was evaluated according to verbal rating scale(VRS).MAIN OUTCOME MEASURES: The analgesia effects and adverse effects in each group RESULTS: The analgesia total effective rate of integrate therapy group was 89% (41/46), in which the effective rate of chemotherapy + PD subgroup was 89% (16/18), the effective rate of radiotherapy +PD subgroup was 88% (14/16), and the effective rate of nuclide +PD subgroup was 92%(11/12). The analgesia total effective rate of mono-therapy group was 64%(16/25), in which the effective rate of chemotherapy was 60% (9/15)and the effective rate of radiotherapy was 70% (7/10).CONCLUSION: The integrate therapy combined with PD, an osteoclast depressant that can against cancer, in the treatment of pain induced by lung cancer bone metastasis achieves satisfactory effectiveness with no additional adverse effects, which could further improve the quality of life of the patients.
Machine-generated Keywords：
Publication Date：2004-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：2( 5714-5715 )